WINTON GROUP Ltd Sells 38,484 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

WINTON GROUP Ltd lessened its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 51.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 36,027 shares of the company’s stock after selling 38,484 shares during the period. WINTON GROUP Ltd owned 0.07% of Voyager Therapeutics worth $285,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Federated Hermes Inc. lifted its position in shares of Voyager Therapeutics by 0.5% in the 2nd quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock worth $4,384,000 after purchasing an additional 2,638 shares during the period. American Century Companies Inc. grew its stake in shares of Voyager Therapeutics by 32.4% in the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock worth $8,063,000 after acquiring an additional 249,659 shares during the period. ClariVest Asset Management LLC grew its stake in shares of Voyager Therapeutics by 2.7% in the second quarter. ClariVest Asset Management LLC now owns 102,822 shares of the company’s stock worth $813,000 after acquiring an additional 2,699 shares during the period. Victory Capital Management Inc. grew its stake in shares of Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after acquiring an additional 1,630 shares during the period. Finally, Rhumbline Advisers grew its position in Voyager Therapeutics by 56.0% during the second quarter. Rhumbline Advisers now owns 72,461 shares of the company’s stock valued at $573,000 after buying an additional 26,014 shares during the period. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Price Performance

NASDAQ VYGR opened at $6.23 on Thursday. The company has a market capitalization of $339.72 million, a PE ratio of -124.58 and a beta of 0.91. The company has a fifty day moving average of $7.39 and a 200 day moving average of $8.14. Voyager Therapeutics, Inc. has a 1 year low of $5.97 and a 1 year high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20. The business had revenue of $29.58 million during the quarter, compared to analysts’ expectations of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same quarter in the previous year, the company earned ($0.51) earnings per share. Research analysts expect that Voyager Therapeutics, Inc. will post -1.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on VYGR shares. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Tuesday, August 20th. Wedbush lowered their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Voyager Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $17.83.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.